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We have characterized the molecular changes underlying the transformation of a JAK2V617F+-myelofibrosis with
trisomy 8, into a JAK2V617F-negative leukemia. Leukemic clone did not carry JAK2V617F mutation, but showed
ASXL1 mutation (R693X). This mutation was identified in a low percentage at diagnosis by next-generation
sequencing. Using this technology in serial specimens during the follow-up, we observed a progressive expansion
of the ASXL1-mutated minor clone, whereas the JAK2V617F+-clone carrying trisomy 8 decreased. Hematologic
progression occurred simultaneously with an ASXL1-R693X-negative lung-cancer. This is the first report showing a
clear association between the expansion of an ASXL1-mutated clone and the leukemic transformation of
myelofibrosis.
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It is known that patients with JAK2V617F+ myeloprolifer-
ative neoplasms (MPNs) can progress to a JAK2V617F¯
acute myeloid leukemia (AML) [1-3]. These two phases of
the disease may represent two different clones [1], how-
ever, the time-dependent clonal hierarchy is just beginning
to be elucidated [4,5].
ASXL1 is the second most frequently mutated gene
after JAK2 (~34.5%) in myelofibrosis (MF) [6]. ASXL1 mu-
tations are also found in solid neoplasms and all types of
myeloid malignancies [7]. They are associated with aggres-
sive disease [8] but their role in leukemic transformation
remains controversial. ASXL1 mutations correlated with
progression to blast-state in myelodysplastic syndromes
and chronic myelomonocytic leukaemia [9,10] while in
MF, they are detectable in most patients at diagnosis [11],
and they are present in chronic- and blast-phases [2] with* Correspondence: fferrermarin@gmail.com
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distribution, and reproduction in any mediumthe same prevalence [6]. These findings suggest that
ASXL1 mutations play a crucial role in the pathogenesis of
MF [6,11] but they do not directly cause a leukemic
phenotype [2,6]. We here characterize the molecular
changes associated to the leukemic transformation of a pa-
tient with primary-MF (PMF) using next-generation se-
quencing (NGS). By the time of the hematologic
progression, the patient also developed a lung adenocar-
cinoma. The relationship between the clonal hierarchy
and phenotype disease over time are discussed.
Case presentation
A 62-year-old male with 126 pack-year smoking history,
cardiomyopathy and chronic-pulmonary disease was re-
ferred to our Department in May’ 2007 for evaluation of
anemia, splenomegaly and fever. Following a peripheral
blood (PB) and a bone marrow (BM) examination, a diag-
nosis of PMF according to WHO criteria was made, IPSS
intermediate-2 [12]. Genetic analysis revealed a trisomy 8
in all 18 metaphases analyzed and the JAK2V617F muta-
tion. With hydroxyurea, the patient achieved a complete
resolution of fever and splenomegaly, and hemoglobinntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Ferrer-Marín et al. Journal of Hematology & Oncology 2013, 6:68 Page 2 of 5
http://www.jhoonline.org/content/6/1/68normalization. Thirty months later, he started with lumbar
pain and leukocytosis (12.9 × 109/L). A new BM biopsy
showed severe fibrosis with osteosclerosis. Due to the
patients’s comorbidities, allogeneic transplant was not pos-
sible and hydroxyurea was continued. In December’ 2010,
the patient developed fever, splenomegaly, marked
leukocytosis (81.3 × 109/L) and required red-cell transfu-
sions. A new BM biopsy confirmed leukemic transform-
ation (Figure 1A) but fluorescence in situ hybridization
(FISH) analysis discarded trisomy 8. Hydroxyurea was in-
creased achieving a good control of leukocyte count. Few
weeks later, he began with back and thoracic pain. A com-
puted tomography (CT) scan revealed a speculated right
lung nodule (Figure 1B). Biopsy confirmed non–small-cell
lung cancer (NSCLC) (T1N0MX) and a PET-CT forFigure 1 Histologic and radiologic studies at the time of leukemic tra
without segmentation (blasts >20%) and dysplastic megakaryocytes. With s
osteoesclerosis was also shown. (B) Chest CT scan showing an increase in
2 cm in size with speculated edges. (C) Positron-emission tomography with
the vertebral bodies; sacrum; extremity bones (specially left humerus); andstaging was made (Figure 1C). Despite starting treatment
for AML with thioguanine, the patient died because of
acute congestive heart and liver failure. A post-mortem
liver biopsy uncovered metastatic infiltration by NSCLC.
Discussion
To further investigate the molecular mechanisms under-
lying neoplastic progression in this case, we performed
JAK2V617F allele burden in PB granulocytes obtained at
three time points, by allele-specific qRT-PCR [13].
JAK2V617F allele percentage decreased from 30% at
diagnosis to undetectable level at blast-phase with an
intermediate value of 20% (Figure 2A). A clonal analysis
with microsatellites for 4 markers on chromosome 9p
flanking JAK2, on PB granulocytes taken at diagnosisnsformation. (A) BM biopsy showing immature myeloid proliferation
ilver staining (right panel), marked reticulin fibrosis associated with
bone density of the vertebral bodies and a right lung nodule of 2 ×
CT showing a markedly increased of 18 F-FDG uptake in the BM of
focal in the spleen.
Figure 2 Clonal progression from diagnosis of PMF to leukemic transformation and death. (A) Dynamic changes in the size of the two
mutated clones, JAK2V617F and ASXL1-R693X, in three time points during follow up: at the time of presentation of PMF, during the evolution and
in blast-phase. (B) Microsatellite analysis on PB granulocytes at diagnosis (left panel) and blast-phase of MF (right panel) for 4 markers on
chromosome 9p flanking JAK2. The positions of microsatellite markers used to identify the common 9pLOH region are shown as vertical lines (C)
ASXL1 sequencing in paired samples of cDNA from PB granulocytes showing one nonsense mutation (R693X) in the ASXL1 gene at blast-phase,
but not at diagnosis (left panel). This mutation was not detected in the hepatic metastatic tissue of lung cancer (right panel).
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zygosity on chromosome 9p (9pLOH), either at diagno-
sis (JAK2V617F+-clone) or at blast-stage (dominant
JAK2V617F¯-clone) (Figure 2B), suggesting that at pres-
entation, two independent clones were likely present in
our patient. To address this question, sequencing of
ASXL1 (exon 12), TET2 (all exons), TP53 (exon 4–9),
IDH1 (R132), IDH2 (R140, R172), c-CBL (exons 8–9) by
Sanger and SRSF2 (exon 1), SF3B1 (exons 14–15) by
NGS (454-GS Junior platform) were performed, in the
same samples, as described [15,16]. At blast-phase, we
identified an ASXL1-nonsense mutation (R693X), which
was not present at diagnosis either by conventionalsequencing (Figure 2C) or by high resolution melting
analysis (not shown). However, by using NGS (sensibility
1%, [17]) we were able to detect the ASXL1-R693X mu-
tation at diagnosis in a very low level (2%). Additionally,
using NGS at two time-points during follow-up, we ob-
served an expansion of the ASXL1-R693X subclone, with
a maximum value of 50% at blast-phase (Figure 2A).
Since ASXL1 has been involved in epithelial malig-
nancy tumorigenesis [18] and cancer [7], we sequenced
ASXL1 gene in the hepatic metastatic tissue of lung cancer,
but ASXL1-R693X mutation was not detected (Figure 2C),
suggesting that at least three malignant clones might be
present.
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phenotype was driven mainly by a JAK2V617F+-domin-
ant clone carrying trisomy 8. During the evolution this
clone declined, whereas the ASXL1-mutated minor clone
expanded, promoting the progression to leukemia. The
reasons for these gradual shifts are unknown. Although
hydroxyurea may induce a decrease in JAK2V617F allele
burden in JAK2V617F+-MPNs [13,19], leukemic trans-
formation in MF can occur without any prior therapy
[20]. Furthermore, ASXL1-R693X mutation, as other
mutations affecting genes with epigenetic role, likely
favor the occurrence of secondary genetic events and, in
association with other cooperating mutations, promotes
blast-crisis [5].
The molecular mechanisms undergoing the myeloid
leukemogenesis promoted by ASXL1 have been recently
reported [21], but in MF, the role of ASXL1 mutations in
leukemic transformation is still unclear [2,6,22]. By using
NGS, we report, for the first time, an association be-
tween expansion of an ASXL1-mutated clone and MF
progression to AML suggesting that in MF, as in other
myeloid malignancies, ASXL1 mutations play a role in
leukemic transformation. Given the prevalence of ASXL1
mutations in patients with MF, determination of ASXL1
mutation status in these patients could help in the mo-
lecular disease monitoring.Consent
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